Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Published bySiska Tedja Modified over 6 years ago

Similar presentations

Presentation on theme: "Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D."— Presentation transcript:

1 Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D. Puri, PhD, Bart H. Steiner, BS, Leanne Holes, BS, MBA, Guan Xing, PhD, Petra Zieglmayer, MD, René Zieglmayer, DI, Patrick Lemell, PhD, Albert Yu, MD  Journal of Allergy and Clinical Immunology  Volume 137, Issue 6, Pages (June 2016) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 CONSORT flow diagram.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 A, Mean (SE) TNSS over time on day 7 for the combined treatment periods. B, Mean (SE) nasal airflow change over time on day 7 for the combined treatment periods. C, Mean (SD) nasal secretion weight for the combined treatment periods. D, Ex vivo basophil activation in whole blood samples on day 7 expressed as the relative percentage of CD63+/CCR3+ cells and the change from baseline. Paired comparisons of idelalisib and placebo were done at each time point for TNSSs. *Significant difference: P < .05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Changes in plasma concentrations of CCL17, CCL22, and IFN-γ during idelalisib therapy. Geometric means with 95% confidence limits are shown. P values were computed by using paired t tests. BL-I, Baseline for idelalisib treatment; BL-P, baseline for placebo treatment; NS, not significant. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D."

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial  Peter Bager, PhD, John Arnved, MD, Steen.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Similar presentations

Ads by Google